Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy

Completed · Phase 2 · Has a placebo group

Conditions studied: Immunoglobulin A (IgA) Nephropathy

In brief

Randomized, placebo-controlled, multi-center, double-blind, proof of concept phase IIa trial and dose evaluation trial of felzartamab in IgAN

Key facts

Study ID
NCT05065970
Run by
HI-Bio, A Biogen Company
People needed
54
Starts
2021-08-31
Expected to finish
2024-05-06
Last updated by the study team
2026-04-28

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.